| Methods |
4‐week placebo phase; inclusion criteria= sitting DBP 95‐115 mm Hg after 4 weeks with less than 7 mm Hg variation from sitting DBP reading at week 2; 12‐week double‐blind treatment |
| Participants |
Losartan 50 mg: n=139(90 males,49 females); median age=55 years; baseline sitting DBP=100.9 mm Hg;
Placebo: n=140(81 males,59 females); median age=54 years; baseline sitting DBP=101.3 mm Hg |
| Interventions |
Losartan 50 mg once daily;
Placebo |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP;
WDAE |
| Notes |
BP change and SD of change reported, endpoint BP reported; endpoint SD reported, BP data from Tables 2 and 3, p. S45; BP measurement device not reported; Jadad score=3; funding source= Merck |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
